Antigenic conservation and immunogenicity of the HIV coreceptor binding site

Journal of Experimental Medicine

Volumn 201, Issue 9, 2005, Pages 1407-1419

  Decker, Julie M ^a,b,c   Bibollet Ruche, Frederic ^a,b,c   Wei, Xiping ^a,b,c   Wang, Shuyi ^a,b,c   Levy, David N ^a,b,c   Wang, Wenquan ^a,b   Delaporte, Eric ^d   Peeters, Martine ^d   Derdeyn, Cynthia A ^e,f   Allen, Susan ^f   Hunter, Eric ^e,f   Saag, Michael S ^b   Hoxie, James A ^g   Hahn, Beatrice H ^b,c   Kwong, Peter D ^h   Robinson, James E ⁱ   Shaw, George M ^a,b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIV MONTPELLIER   (France)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR; EPITOPE; HIV 1 ENVELOPE GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS RECEPTOR;

ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; BINDING SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMA; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, CD4; CROSS REACTIONS; EPITOPES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NEUTRALIZATION TESTS; RECEPTORS, CHEMOKINE; SEQUENCE ALIGNMENT;

EID: 20844448731     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20042510     Document Type: Article

References (79)

1. Albert, J., B. Abrahamsson, and K. Nagy. 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS. 4:107-112.
2. Moog, C., H.J. Fleury, I. Pellegrin, A. Kirn, and A.M. Aubertin. 1997. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71:3734-3741.
3. Wei, X., J.M. Decker, S. Wang, H. Hui, J.C. Kappes, X. Wu, J.F. Salazar-Gonzalez, M.G. Salazar, J.M. Kilby, M.S. Saag, et al. 2003. Antibody neutralization and escape by HIV-1. Nature. 422:307-312.
4. Richman, D.D., T. Wrin, S.J. Little, and C.J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA. 100:4144-4149.
5. Pilgrim, A.K., G. Pantaleo, O.J. Cohen, L.M. Fink, J.Y. Zhou, J.T. Zhou, D.P. Bolognesi, A.S. Fauci, and D.C. Montefiori. 1997. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176:924-932.
6. Montefiori, D.C., T.S. Hill, H.T. Vo, B.D. Walker, and E.S. Rosenberg. 2001. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 75:10200-10207.
7. Parren, P.W., J.P. Moore, D.R. Burton, and Q.J. Sattentau. 1999. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS. 13:S137-S162.
8. Kwong, P.D., R. Wyatt, J. Robinson, R.W. Sweet, J. Sodroski, and W.A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:648-659.
9. Wyatt, R., P.D. Kwong, E. Desjardins, R.W. Sweet, J. Robinson, W.A. Hendrickson, and J.G. Sodroski. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:705-711.
10. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens and immunogens. Science. 280:1884-1888.
11. Kwong, P.D., M.L. Doyle, D.J. Casper, C. Cicala, S.A. Leavitt, S. Majeed, T.D. Steenbeke, M. Venturi, I. Chaiken, M. Fung, et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 420:678-682.
12. Labrijn, A.F., P. Poignard, A. Raja, M.B. Zwick, K. Delgado, M. Franti, J. Binley, V. Vivona, C. Grundner, C.C. Huang, et al. 2003. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77:10557-10565.
13. Burton, D.R., R.C. Desrosiers, R.W. Doms, W.C. Koff, P.D. Kwong, J.P. Moore, G.J. Nabel, J. Sodroski, I.A. Wilson, and R.T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236.
14. Zolla-Pazner, S. 2004. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 4:199-210.
15. Broliden, P.A., A. von Gegerfelt, P. Clapham, J. Rosen, E.M. Fenyo, B. Wahren, and K. Broliden. 1992. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc. Natl. Acad. Sci. USA. 89:461-465.
16. Scala, G., X. Chen, W. Liu, J.N. Telles, O.J. Cohen, M. Vaccarezza, T. Igarashi, and A.S. Fauci. 1999. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. J. Immunol. 162:6155-6161.
17. Opalka, D., A. Pessi, E. Bianchi, G. Ciliberto, W. Schleif, M. McElhaugh, R. Danzeisen, R. Geleziunas, M. Miller, D.M. Eckert, et al. 2004. Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J. Immunol. Methods. 287:49-65.
18. Sequence Compendium, H.I.V. 2002. Kuiken, C.L., B. Foley, E. Freed, B. Hahn, B. Korber, P.A. Marx, F. McCutchan, J.W. Mellors, and S. Wolinsky, eds. Los Alamos National Laboratory, Los Alamos, NM. LA-UR 03-3564.
19. Weiss, R.A., P.R. Clapham, J.N. Weber, D. Whitby, R.S. Tedder, T. O'Connor, S. Chamaret, and L. Montagnier. 1988. HIV-2 antisera cross-neutralize HIV-1. AIDS. 2:95-100.
20. Bottiger, B., A. Karlsson, P.A. Andreasson, A. Naucler, C.M. Costa, E. Norrby, and G. Biberfeld. 1990. Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site. J. Virol. 64:3492-3499.
21. Thomas, E.R., C. Shotton, R.A. Weiss, P.R. Clapham, and A. McKnight. 2003. CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS. 17:291-300.
22. Deng, H.K., D. Unutmaz, V.N. KewalRamani, and D.R. Littman. 1997. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature. 388:296-300.
23. Zhang, Y., B. Lou, R.B. Lal, A. Gettie, P.A. Marx, and J.P. Moore. 2000. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74:6893-6910.
24. Sattentau, Q.J., J.P. Moore, F. Vignaux, F. Traincard, and P. Poignard. 1993. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J. Virol. 67:7383-7393.
25. Wu, L., N.P. Gerard, R. Wyatt, H. Choe, C. Paroliu, N. Ruffing, A. Borsetti, A.A. Cardoso, E. Desjardin, W. Newman, et al. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 384:179-183.
26. Trkola, A., T. Dragic, J. Arthos, J.M. Binley, W.C. Olson, G.P. Allaway, C. Cheng-Mayer, J. Robinson, PJ. Maddon, and J.P. Moore. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 384:184-187.
27. Wyatt, R., J. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
28. Salzwedel, K., E.D. Smith, B. Dey, and E.A. Berger. 2000. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J. Virol. 74:326-333.
29. Rizzuto, C.D., R. Wyatt, N. Hernandez-Ramos, Y. Sun, P.D. Kwong, W.A. Hendrickson, and J. Sodroski. 1998. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 280:1949-1953.
30. Rizzuto, C., and J. Sodroski. 2000. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses. 16:741-749.
31. Xiang, S.H., N. Doka, R.K. Choudhary, J. Sodroski, and J.E. Robinson. 2002. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retrovirus. 18:1207-1217.
32. Xiang, S.H., L. Wang, M. Abreu, C.C. Huang, P.D. Kwong, E. Rosenberg, J.E. Robinson, and J. Sodroski. 2003. Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology. 315:124-134.
33. Huang, C.C., M. Venturi, S. Majeed, M.J. Moore, S. Phogat, M.Y. Zhang, D.S. Dimitrov, W.A. Hendrickson, J. Robinson, J. Sodroski, et al. 2004. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. USA. 101:2706-2711.
34. Gao, F., L. Yue, A.T. White, P.G. Pappas, J. Barchue, A.P. Hanson, B.M. Greene, P.M. Sharp, G.M. Shaw, and B.H. Hahn. 1992. Human infection by genetically diverse SIVSM-related H1V-2 in west Africa. Nature. 358:495-499.
35. Barnett, S.W., M. Quiroga, A. Werner, D. Dina, and J.A. Levy. 1993. Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodeficiency virus type 2 UC1 strain. J. Virol 67:1006-1014.
36. Reeves, J.D., and R.W. Doms. 2002. Human immunodeficiency virus type 2. J. Gen. Virol. 83:1253-1265.
37. Kolchinsky, P., E. Kiprilov, and J. Sodroski. 2001. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J. Virol. 75:2041-2050.
38. Kolchinsky, P., T. Mirzabekov, M. Farzan, E. Kiprilov, M. Cayabyab, L.J. Mooney, H. Choe, and J. Sodroski. 1999. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J. Virol. 73:8120-8126.
39. Hoffinan, T.L., C.C. LaBranche, W. Zhang, G. Canziani, J. Robinson, I. Chaiken, J.A. Hoxie, and R.W. Doms. 1999. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc. Natl. Acad. Sci. USA. 96:6359-6364.
40. Pugach, P., S.E. Kuhmann, J. Taylor, A.J. Marozsan, A. Snyder, T. Ketas, S.M. Wolinsky, B.T. Korber, and J.P. Moore. 2004. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology. 321:8-22.
41. Zhang, P.P., P. Bouma, E.J. Park, J.B. Margolick, J.E. Robinson, S. Zolla-Pazner, M.N. Flora, and G.V. Quinnan Jr. 2002. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J. Virol. 76:644-655.
42. Mirzabekov, T., N. Bannert, M. Farzan, W. Hofmann, P. Kolchinsky, L. Wu, R. Wyatt, and J. Sodroski. 1999. Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor. J. Biol. Chem. 274:28745-28750.
43. Colman, P.M. 1997. Virus versus antibody. Structure. 5:591-593.
44. Hewat, E., and D. Blaas. 2001. Structural studies on antibody interacting with viruses. Curr. Top. Microbiol. Immunol. 260:29-44.
45. Bizebard, T., C. Barbey-Martin, D. Fleury, B. Gigant, B. Barrere, J.J. Skehel, and M. Knossow. 2001. Structural studies on viral escape from antibody neutralization. Curr. Top. Microbiol. Immunol. 260:55-64.
46. Darbha, R., S. Phogat, A.F. Labrijn, Y. Shu, Y. Gu, M. Andrykovitch, M.Y. Zhang, R. Pantophlet, L. Martin, C. Vita, et al. 2004. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry. 43:1410-1417.
47. Salzwedel, K., and E.A. Berger. 2000. Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41. Proc. Natl. Acad. Sci. USA. 97:12794-12799.
48. Kolchinsky, P., E. Kiprilov, P. Bartley, R. Rubinstein, and J. Sodroski. 2001. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J. Virol. 75:3435-3443.
49. Wei, X., S.K. Ghosh, M.E. Taylor, V.A. Johnson, E.A. Emini, P. Deutsch, J.D. Lifson, S. Bonhoeffer, M.A. Nowak, B.H. Hahn, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:117-122.
50. Gorry, P.R., J. Taylor, G.H. Holm, A. Mehle, T. Morgan, M. Cayabyab, M. Farzan, H. Wang, J.E. Bell, K. Kunstman, et al. 2002. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J. Virol. 76:6277-6292.
51. Moore, J.P., S.G. Kitchen, P. Pugach, and J.A. Zack. 2004. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses. 20:111-126.
52. Derdeyn, C.A., J.M. Decker, F. Bibollet-Ruche, J.L. Mokili, M. Muldoon, S.A. Denham, M.L. Heil, F. Kasolo, R. Musonda, B.H. Hahn, et al. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 303:2019-2022.
53. Xiang, S.H., P.D. Kwong, R. Gupta, C.D. Rizzuto, D.J. Casper, R. Wyatt, L. Wang, W.A. Hendrickson, M.L. Doyle, and J. Sodroski. 2002. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 76:9888-9899.
54. Liao, H.X., S.M. Alam, J.R. Mascola, J. Robinson, B. Ma, D.C. Montefiori, M. Rhein, L.L. Sutherland, R. Scearce, and B.F. Haynes. 2004. Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. J. Virol. 78:5270-5278.
55. Fouts, T.R., R. Tuskan, K. Godfrey, M. Reitz, D. Hone, G.K. Lewis, and A.L. DeVico. 2000. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J. Virol. 74:11427-11436.
56. Purtscher, M., A. Trkola, G. Gruber, A. Buchacher, R. Predl, F. Steindl, C. Tauer, R. Berger, N. Barrett, A. Jungbauer, and H. Katinger. 1994. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 10:1651-1658.
57. Buchacher, A., R. Predl, K. Strutzenberger, W. Steinfellner, A. Trkola, M. Purtscher, G. Gruber, C. Tauer, F. Steindl, A. Jungbauer, and H. Katinger. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses. 10:359-369.
58. Zwick, M.B., A.F. Labrijn, M. Wang, C. Spenlehauer, E.O. Saphire, J.M. Binley, J.P. Moore, G. Stiegler, H. Katinger, D.R. Burton, and P.W. Parren. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus tpe 1 glycoprotein gp41. J. Virol. 75:10892-10905.
59. Ho, J., K.S. MacDonald, and B.H. Barber. 2002. Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint. Vaccine. 20:1169-1180.
60. Liang, X., S. Munshi, J. Shendure, G. Mark III, M.E. Davies, D.C. Freed, D.C. Montefiori, and J.W. Shiver. 1999. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine. 17:2862-2872.
61. McGaughey, G.B., M. Citron, R.C. Danzeisen, R.M. Freidinger, V.M. Garsky, W.M. Hurni, J.G. Joyce, X. Liang, M. Miller, J. Shiver, and M.J. Bogusky. 2003. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry. 42:3214-3223.
62. Tian, Y., C.V. Ramesh, X. Ma, S. Naqvi, T. Patel, T. Cenizal, M. Tiscione, K. Diaz, T. Crea, E. Arnold, et al. 2002. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints. J. Pept. Res. 59:264-276.
63. Barnett, S.W., S. Lu, I. Srivastava, S. Cherpelis, A. Gertie, J. Blanchard, S. Wang, I. Mboudjeka, L. Leung, Y. Lian, et al. 2001. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) 7envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75:5526-5540.
64. Mascola, J.R., S.W. Snyder, O.S. Weislow, S.M. Belay, R.B. Belshe, D.H. Schwartz, M.L. Clements, R. Dolin, B.S. Graham, G.J. Gorse, et al. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1.J. Infect. Dis. 173:340-348.
65. Binley, J.M., T. Wrin, B. Korber, M.B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252.
66. Ofek, G., M. Tang, A. Sambor, H. Katinger, J.R. Mascola, R. Wyatt, and P.D. Kwong. 2004. Structure and mechanistic analysis of the antihuman immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.J. Virol. 78:10724-10737.
67. Levy, D.N., G.M. Aldrovandi, O. Kutsch, and G.M. Shaw. 2004. Dynamics of HIV-1 recombination in its natural target cells. Proc. Natl. Acad. Sci. USA. 101:4204-4209.
68. Robertson, D.L., B.H. Hahn, and P.M. Sharp. 1995. Recombination in AIDS viruses. J. Mol. Evol. 40:249-259.
69. Wu, X., H. Liu, H. Xiao, J. Kim, P. Seshaiah, G. Natsoulis, J.D. Boeke, B.H. Hahn, and J.C. Kappes. 1995. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx.J. Virol. 69:3389-3398.
70. Kumar, P., H.X. Hui, J.C. Kappes, B.S. Haggarty, J.A. Hoxie, S.K. Arya, G.M. Shaw, and B.H. Hahn. 1990. Molecular characterization of an attenuated human immunodeficiency virus type 2 isolate. J. Virol. 64:890-901.
71. Thali, M., J.P. Moore, C. Furman, M. Charles, D.D. Ho, J. Robinson, and J. Sodroski. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
72. Choe, H., W. Li, P.L. Wright, N. Vasilieva, M. Venturi, C.C. Huang, C. Grundner, T. Dorfman, M.B. Zwick, L. Wang, et al. 2003. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell. 114:161-170.
73. Immunology, H.I.V. and HIV/SIV Vaccine Databases 2003. Korber, B.T.M., C. Brander, B.F. Haynes, R. Koup, J.P. Moore, B.D. Walker, and D.I. Watkins, eds. Los Alamos National Laboratory, Los Alamos, NM. LA-UR 04-8162.
74. Cole, K.S., M. Alvarez, D.H. Elliott, H. Lam, E. Martin, T. Chau, K. Micken, J.L. Rowles, J.E. Clements, M. Murphey-Corb, et al. 2001. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology. 290:59-73.
75. Robinson, J.E., K.S. Cole, D.H. Elliott, H. Lam, A.M. Amedee, R. Means, R.C. Desrosiers, J. Clements, R.C. Montelaro, and M. Murphey-Corb. 1998. Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine. AIDS Res. Hum. Retroviruses. 14:1253-1262.
76. Cormier, E.G., D.N. Tran, L. Yukhayeva, W.C. Olson, and T. Dragic. 2001. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J. Virol. 75:5541-5549.
77. Beyl, W., L. Nehring, L. Gurtler, J. Eberle, and F. Deinhardt. 1987. AIDS verusacht durch HIV-2. Munch. Med. Wochenschr. 129:895-896.
78. Gao, F., L. Yue, P.M. Sharp, and B.H. Hahn. 1993. Genetic typing of HIV-2 from a Senegalese/German heterosexual transmission. AIDS Res. Hum. Retroviruses. 9:703-704.
79. Schulz, T.F., D. Whitby, J.G. Hoad, T. Corrah, H. Whittle, and R.A. Weiss. 1990. Biological and molecular variability of human immunodeficiency virus type 2 isolates from the Gambia. J. Virol. 64:5177-5182.